Geode Capital Management LLC Cuts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Geode Capital Management LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,097,543 shares of the medical research company's stock after selling 124,448 shares during the quarter. Geode Capital Management LLC owned approximately 2.26% of IQVIA worth $967,585,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock worth $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Farallon Capital Management LLC increased its position in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company's stock worth $618,046,000 after purchasing an additional 86,870 shares in the last quarter. FMR LLC boosted its position in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares in the last quarter. Impax Asset Management Group plc grew its stake in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after buying an additional 157,809 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of IQVIA by 0.8% during the second quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company's stock worth $320,170,000 after buying an additional 11,715 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.3 %

IQVIA stock traded down $0.70 during mid-day trading on Thursday, reaching $200.37. The stock had a trading volume of 1,143,937 shares, compared to its average volume of 1,186,217. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The stock's 50-day simple moving average is $213.40 and its 200-day simple moving average is $224.61. The firm has a market capitalization of $36.37 billion, a PE ratio of 26.29, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on IQV shares. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They issued a "buy" rating and a $276.00 target price for the company. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Leerink Partners reissued an "outperform" rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Robert W. Baird cut their price target on shares of IQVIA from $213.00 to $212.00 and set a "neutral" rating on the stock in a report on Wednesday. Finally, Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus target price of $257.60.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.